论文部分内容阅读
目的:评价胎儿生长受限(FGR)对高血压和先兆子痫患者结局的影响。方法:对437例使用钙离子拮抗剂的妊高症患者进行回顾性研究,并将其分为四组:妊高症-适于胎龄儿组(GH-AGA)组:244例;妊高症-胎儿生长受限组(GH-FGR):78例;先兆子痫-适于胎龄儿组(PE-AGA):76例;先兆子痫-胎儿生长受限组(PE-FGR):39例。测定指标:是否需要二线治疗,是否延期妊娠,是否增加产褥期时间,分娩年龄,新生儿出生体重,围产期死亡率和是否发生新生儿畸形。结果:存在胎儿生长受限的妊高症和先兆子痫患者的二线治疗明显增加:GH-AGA组:15.4%;GH-FGR组:32.8%;PE-AGA组:28%;PE-FGR组:50%。在妊高症和先兆子痫的患者中与适于胎龄儿组相比,胎儿生长受限组延期妊娠上有统计学差异:(31.3±5.4vs20.7±3.4天和35.3±4.5vs22.2±3.1天;P<0.001)。分娩年龄(P<0.001):35.5±2.3岁vs35.6±2.5岁和34.4±1.7岁vs33.1±2.3岁。出生体重明显不同:(P<0.001):2,271±759.1克vs1,817.59±396.9克和2,196±685.17vs1,465.80±441.7克。死亡率GH-FGR组2.56%(2例)和PE-FGR组10.2%(4例)。没有新生儿畸形发生。结论:妊高症和先兆子痫增加了低出生体重的风险,另一方面FGR对高血压和先兆子痫患者的结局,围产期发病率和胎儿死亡率以及对孕妇进行有效的管理和治疗是一个决定性因素。
PURPOSE: To evaluate the impact of fetal growth restriction (FGR) on outcome in patients with hypertension and preeclampsia. Methods: A total of 437 hypertensive patients with calcium antagonist were retrospectively studied and divided into four groups: pregnancy-induced hypertension (gestational age group) (GH-AGA) group: 244 cases, pregnancy-induced hypertension Fetal growth restriction group (GH-FGR): 78 cases; Pre-eclampsia-suitable for gestational age group (PE-AGA): 76 cases; Pre-eclampsia-Fetal growth restriction group 39 cases. MEASUREMENTS MEASURES: Whether second-line treatment is needed, whether pregnancy is extended, whether the time for puerperium is increased, the age of childbirth, the birth weight of newborns, the perinatal mortality rate and the occurrence of neonatal malformations. RESULTS: There was a significant increase in second-line treatment of patients with pre-eclampsia and preeclampsia with limited fetal growth: 15.4% for GH-AGA; 32.8% for GH-FGR; 28% for PE-AGA; : 50%. There was a statistically significant difference in delayed pregnancy in the FGR group between patients with gestational hypertension and pre-eclampsia compared with those with gestational age (31.3 ± 5.4 vs. 20.7 ± 3.4 days and 35.3 ± 4.5 vs. 22). 2 ± 3.1 days; P <0.001). Childbirth (P <0.001): 35.5 ± 2.3 vs 35.6 ± 2.5 and 34.4 ± 1.7 vs 33.1 ± 2.3. Significantly different birth weight: (P <0.001): 2,271 ± 759.1 grams vs 1,817.59 ± 396.9 grams and 2,196 ± 685.17 vs 1,465.80 ± 441.7 grams. Mortality was 2.56% (2 cases) in the GH-FGR group and 10.2% (4 cases) in the PE-FGR group. No newborn deformity occurred. Conclusions Pregnancy-induced hypertension and pre-eclampsia increase the risk of low birth weight. On the other hand, FGR has an effect on the outcomes of hypertension and pre-eclampsia, perinatal morbidity and fetal mortality, and on the management and treatment of pregnant women Is a decisive factor.